All In Biotech

Drug Trial Radar · NCT07889245

A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With Established or Increased Risk of Atherosclerotic Cardiovascular Disease.

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

192

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Aug 24, 2028

Study completion Dec 24, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic cardiovascular disease (diagnosed or at increased risk).

Conditions

  • sHTG
  • HTG With ASCVD (Diagnosed or at Increased Risk)

Interventions

  • FXR0906 injectionDrug

    2 doses of FXR0906 (dose 1 ) by subcutaneous (sc) injection

  • FXR0906 injectionDrug

    2 doses of FXR0906 (dose 2 ) by subcutaneous (sc) injection

  • FXR0906 injectionDrug

    2 doses of FXR0906 (dose 3 ) by subcutaneous (sc) injection

  • PlaceboDrug

    The placebo is normal saline (0.9%) and 2 doses of volume matched placebo will be administrated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. percent change from baseline at week 24 in fasting triglycerides(TG)Time frame: baseline, week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.